Skip to main content
. 2018 Jul 3;9(51):29587–29600. doi: 10.18632/oncotarget.25640

Figure 6. In vitro evaluation of everolimus and olaparib combinations in BT20 and HCC1395 breast cancer cell lines.

Figure 6

(A) Drug dose matrix data representing percentage of growth inhibitions (top panels), matrix with the loewe excess (middle panels) and isobolograms (bottom panels). (B) Western blot analysis of FANCD2, P-H2AX, S6/P-S6, SUV39H1 and GAPDH in BT20 and HCC1395 cell lines treated by everolimus and olaparib (10 μM).